Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
X Song, L Cao, B Ni, J Wang, X Qin, X Sun… - Frontiers in …, 2023 - frontiersin.org
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer
S Nishihara, T Yamaoka, F Ishikawa, K Higuchi… - Genes, 2022 - mdpi.com
Homeostasis is achieved by balancing cell survival and death. In cancer cells, especially
those carrying driver mutations, the processes and signals that promote apoptosis are …
those carrying driver mutations, the processes and signals that promote apoptosis are …
Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer
There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine
kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven …
kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven …
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
Z Chen, KA Vallega, D Wang, Z Quan, S Fan… - Journal of Experimental …, 2024 - rupress.org
The inevitable acquired resistance to osimertinib (AZD9291), an FDA-approved third-
generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with …
generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with …
Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors
Expression of programmed death-ligand 1 (PD-L1) on cancer cells is a critical mechanism
contributing to immunosuppression and immune escape. PD-L1 expression may also affect …
contributing to immunosuppression and immune escape. PD-L1 expression may also affect …
Dysregulation of a lncRNA within the TNFRSF10A locus activates cell death pathways
TJ Kaczynski, NJ Husami, ED Au, MH Farkas - Cell Death Discovery, 2023 - nature.com
TNFRSF10A (tumor necrosis factor receptor superfamily member 10A) encodes a cell
surface receptor protein involved in apoptotic, necroptotic, and inflammatory pathways …
surface receptor protein involved in apoptotic, necroptotic, and inflammatory pathways …
ZnO nanomaterials target mitochondrial apoptosis and mitochondrial autophagy pathways in cancer cells
Y Li, J Li, Y Lu, Y Ma - Cell Biochemistry and Function, 2024 - Wiley Online Library
In recent years, the application of engineering nanomaterials has significantly contributed to
the development of various biomedical fields. Zinc oxide nanomaterials (ZnO NMts) have …
the development of various biomedical fields. Zinc oxide nanomaterials (ZnO NMts) have …
[HTML][HTML] The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib …
C Liu, L Qian, KA Vallega, G Ma, D Zong… - American journal of …, 2022 - ncbi.nlm.nih.gov
Lung cancer remains the leading cause of cancer deaths worldwide despite advances in
knowledge in cancer biology and options of various targeted therapies. Efforts in identifying …
knowledge in cancer biology and options of various targeted therapies. Efforts in identifying …
[HTML][HTML] METTL7B serves as a prognostic biomarker and promotes metastasis of lung adenocarcinoma cells
R Li, C Mu, Y Cao, Y Fan - Annals of Translational Medicine, 2022 - ncbi.nlm.nih.gov
Background To research the correlation between the prognosis of patients suffering from
lung adenocarcinoma (LUAD) and methyltransferase like 7B (METTL7B) expression …
lung adenocarcinoma (LUAD) and methyltransferase like 7B (METTL7B) expression …
[HTML][HTML] P2RY14 downregulation in lung adenocarcinoma: a potential therapeutic target associated with immune infiltration
T Xu, S Xu, Y Yao, X Chen, Q Zhang… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background The current study aimed to investigate the interrelation between P2RY14 and
the prognosis of patients suffering from lung adenocarcinoma (LUAD) following surgery …
the prognosis of patients suffering from lung adenocarcinoma (LUAD) following surgery …